Related references
Note: Only part of the references are listed.Risk stratification of intermediate-risk acute myeloid leukemia: integrative analysis of a multitude of gene mutation and gene expression markers
Veronika Rockova et al.
BLOOD (2011)
CLEC5A (MDL-1) is a novel PU.1 transcriptional target during myeloid differentiation
Jasmin Batliner et al.
MOLECULAR IMMUNOLOGY (2011)
PML/RARα Targets Promoter Regions Containing PU.1 Consensus and RARE Half Sites in Acute Promyelocytic Leukemia
Kankan Wang et al.
CANCER CELL (2010)
PML-RARα/RXR Alters the Epigenetic Landscape in Acute Promyelocytic Leukemia
Joost H. A. Martens et al.
CANCER CELL (2010)
A functional RNAi screen identifies hexokinase 1 as a modifier of type II apoptosis
Anja Schindler et al.
CELLULAR SIGNALLING (2010)
Clinical Utility of Microarray-Based Gene Expression Profiling in the Diagnosis and Subclassification of Leukemia: Report From the International Microarray Innovations in Leukemia Study Group
Torsten Haferlach et al.
JOURNAL OF CLINICAL ONCOLOGY (2010)
The anti-apoptotic gene BCL2A1 is a novel transcriptional target of PU.1
M. Jenal et al.
LEUKEMIA (2010)
NDRG1/2 expression is inhibited in primary acute myeloid leukemia
Mario P. Tschan et al.
LEUKEMIA RESEARCH (2010)
Regulation and Cytoprotective Role of Hexokinase III
Eugene Wyatt et al.
PLOS ONE (2010)
Acute promyelocytic leukaemia: novel insights into the mechanisms of cure
Hugues de The et al.
NATURE REVIEWS CANCER (2010)
Role of mitochondria-associated hexokinase II in cancer cell death induced by 3-bromopyruvate
Zhao Chen et al.
BIOCHIMICA ET BIOPHYSICA ACTA-BIOENERGETICS (2009)
High throughput digital quantification of mRNA abundance in primary human acute myeloid leukemia samples
Jacqueline E. Payton et al.
JOURNAL OF CLINICAL INVESTIGATION (2009)
Evaluation of the Role of Hexokinase Type II in Cellular Proliferation and Apoptosis Using Human Hepatocellular Carcinoma Cell Lines
Keun Jae Ahn et al.
JOURNAL OF NUCLEAR MEDICINE (2009)
Downregulation of the hexokinase II gene sensitizes human colon cancer cells to 5-fluorouracil
Qiu-Ping Peng et al.
CHEMOTHERAPY (2008)
PU.1: A crucial and versatile player in hematopoiesis and leukemia
Philippe Kastner et al.
INTERNATIONAL JOURNAL OF BIOCHEMISTRY & CELL BIOLOGY (2008)
PU.1 binding to the p53 family of tumor suppressors impairs their transcriptional activity
M. P. Tschan et al.
ONCOGENE (2008)
ATRA resolves the differentiation block in t(15;17) acute myeloid leukemia by restoring PU.1 expression
BU Mueller et al.
BLOOD (2006)
Autologous bone marrow transplantation as consolidation therapy in the treatment of adult patients under 60 years with acute myeloid leukaemia in first complete remission: a prospective randomized Dutch-Belgian Haemato-Oncology Co-operative Group (HOVON) and Swiss Group for Clinical Cancer Research (SAKK) trial
DA Breems et al.
BRITISH JOURNAL OF HAEMATOLOGY (2005)
The value of fludarabine in addition to ARA-C and G-CSF in the treatment of patients with high-risk myelodysplastic syndromes and AML in elderly patients
GJ Ossenkoppele et al.
BLOOD (2004)
Alternative splicing of the human cyclin D-binding Myb-like protein (hDMP1) yields a truncated protein isoform that alters macrophage differentiation patterns
MP Tschan et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2003)
Effect of priming with granulocyte colony-stimulating factor on the outcome of chemotherapy for acute myeloid leukemia
B Löwenberg et al.
NEW ENGLAND JOURNAL OF MEDICINE (2003)
Isozymes of mammalian hexokinase: structure, subcellular localization and metabolic function
JE Wilson
JOURNAL OF EXPERIMENTAL BIOLOGY (2003)
Chromatin immunoprecipitation analysis fails to support the latency model for regulation of p53 DNA binding activity in vivo
MD Kaeser et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2002)